MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596178 | Name: Metachrome yellow
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Metachrome yellow is a dye.

Chemical Structure

Metachrome yellow
CAS# 584-42-9

Theoretical Analysis

MedKoo Cat#: 596178

Name: Metachrome yellow

CAS#: 584-42-9

Chemical Formula: C13H8N3NaO5

Exact Mass: 0.0000

Molecular Weight: 309.21

Elemental Analysis: C, 50.50; H, 2.61; N, 13.59; Na, 7.43; O, 25.87

Price and Availability

Size Price Availability Quantity
25g USD 285.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Metachrome yellow; Alizarin Yellow GG; Java Unichrome Yellow GT; RV 1; C.I. 14025; Acid Chrome Yellow 2GW;
IUPAC/Chemical Name
sodium (E)-2-hydroxy-5-((3-nitrophenyl)diazenyl)benzoate
InChi Key
ZHFPEICFUVWJIS-WPDLWGESSA-M
InChi Code
InChI=1S/C13H9N3O5.Na/c17-12-5-4-9(7-11(12)13(18)19)15-14-8-2-1-3-10(6-8)16(20)21;/h1-7,17H,(H,18,19);/q;+1/p-1/b15-14+;
SMILES Code
O=C([O-])C1=CC(/N=N/C2=CC=CC([N+]([O-])=O)=C2)=CC=C1O.[Na+]
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM.
In vitro activity:
In this study, PD0325901, an oral potent ERK inhibitor, strongly enhanced the efficacy of PD-1 antibody in vitro and in vivo models in non-small cell lung carcinoma (NSCLC) cells. Mechanistically, PD0325901 or shRNA-ERK1/2 significantly downregulated the PD-L1 expression in NSCLC cells and increased the CD3+ T cells infiltration and functions in tumor tissue. This study demonstrates that PD0325901, an ERK inhibitor, can enhance the efficacy of PD-1 blockage against NSCLC in vitro and in vivo models. Reference: Acta Pharm Sin B. 2021 Oct;11(10):3120-3133. https://pubmed.ncbi.nlm.nih.gov/34729305/
In vivo activity:
Animal studies used a destabilization of the medial meniscus (DMM) model and injected 5 mg/kg or 10 mg/kg of PD0325901 compound into each experimental group of mice. This study found that PD0325901 significantly reduced osteochondral pathological changes in post-OA subchondral bone destruction. Reference: Bioorg Chem. 2023 Mar;132:106321. https://pubmed.ncbi.nlm.nih.gov/36642020/
Solvent mg/mL mM comments
Solubility
DMSO 56.0 181.11
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 309.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Luo M, Xia Y, Wang F, Zhang H, Su D, Su C, Yang C, Wu S, An S, Lin S, Fu L. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharm Sin B. 2021 Oct;11(10):3120-3133. doi: 10.1016/j.apsb.2021.03.010. Epub 2021 Mar 9. PMID: 34729305; PMCID: PMC8546891. 2. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29. PMID: 20587665; PMCID: PMC2935263. 3. Jiang T, Gong Y, Zhang W, Qiu J, Zheng X, Li Z, Yang G, Hong Z. PD0325901, an ERK inhibitor, attenuates RANKL-induced osteoclast formation and mitigates cartilage inflammation by inhibiting the NF-κB and MAPK pathways. Bioorg Chem. 2023 Mar;132:106321. doi: 10.1016/j.bioorg.2022.106321. Epub 2022 Dec 30. PMID: 36642020. 4. Bobyn JD, Deo N, Little DG, Schindeler A. Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation. J Orthop Sci. 2021 Jul;26(4):684-689. doi: 10.1016/j.jos.2020.05.016. Epub 2020 Jul 23. PMID: 32713795.
In vitro protocol:
1. Luo M, Xia Y, Wang F, Zhang H, Su D, Su C, Yang C, Wu S, An S, Lin S, Fu L. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharm Sin B. 2021 Oct;11(10):3120-3133. doi: 10.1016/j.apsb.2021.03.010. Epub 2021 Mar 9. PMID: 34729305; PMCID: PMC8546891. 2. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29. PMID: 20587665; PMCID: PMC2935263.
In vivo protocol:
1. Jiang T, Gong Y, Zhang W, Qiu J, Zheng X, Li Z, Yang G, Hong Z. PD0325901, an ERK inhibitor, attenuates RANKL-induced osteoclast formation and mitigates cartilage inflammation by inhibiting the NF-κB and MAPK pathways. Bioorg Chem. 2023 Mar;132:106321. doi: 10.1016/j.bioorg.2022.106321. Epub 2022 Dec 30. PMID: 36642020. 2. Bobyn JD, Deo N, Little DG, Schindeler A. Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation. J Orthop Sci. 2021 Jul;26(4):684-689. doi: 10.1016/j.jos.2020.05.016. Epub 2020 Jul 23. PMID: 32713795.
1: Weber A, Wachowitz R. [The detection of salmonellas using Rambach agar]. Berl Munch Tierarztl Wochenschr. 1994 Feb;107(2):43-4. German. PubMed PMID: 7993335. 2: Hofer E, Silva CH. An evaluation of the efficiency of enrichment media in the isolation process for Vibrio parahaemolyticus. Zentralbl Bakteriol Mikrobiol Hyg A. 1984 Apr;256(4):456-65. PubMed PMID: 6377759. 3: Tiagunenko IuV. [Suppression of the conjugational transfer of derepressed R factors by the dye, metachrome yellow]. Antibiotiki. 1975 Apr;20(4):358-62. Russian. PubMed PMID: 1108773. 4: Mayer H, Schindler S, Weisser W. [Investigations of some metachrome-yellow-preparations as an basic ingredient for metachromgelb-wasserblau-laktose-agar (Gassners medium) (author's transl)]. Zentralbl Bakteriol Orig A. 1975;230(3):406-14. German. PubMed PMID: 49992. 5: SPROSSIG M, MEYER M. [Comparative studies on the efficiency of bromthymol blue-metachrome yellow-lactose agar and bile citrate agar in combination with potassium tetra-thionate broth in the diagnosis of typhoid, paratyphoid and enteritis bacteria]. Dtsch Gesundheitsw. 1955 Nov 3;10(44):1436-40. German. PubMed PMID: 13277421.